Clinical trials
Placebo clinical trials
Below are recruiting placebo clinical trials, each written for real people, not researchers. We’re tracking 5,230 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06955416RecruitingPhase 2/Phase 3
REAMBERIN for rehydration in diabetic ketoacidosis
This trial tests a solution called REAMBERIN to help rehydrate people with diabetic ketoacidosis (DKA). If you are 18–75 and have DKA with very high blood sugar and acidic blood, you may be able to join.
ArkhangelskAges 18–75 - NCT06955975Recruiting
Pectin supplement for frailty in older adults
This study tests if daily pectin, a fiber found in fruits, can improve strength and health in older adults who are frail or pre-frail. It compares pectin to a placebo over time.
Nottingham, NottinghamAges 65 years+ - NCT06956742Recruiting
Breathing device study for COPD shortness of breath after exercise
This trial tests a device that briefly opens your airways to help release trapped air after exercise. It may reduce shortness of breath and improve your daily life with COPD.
Rouen, NormandyAges 18 years+ - NCT06956781Recruiting
Finding the best treatment for childhood PTSD
This study tests different ways to help children ages 8-17 who have PTSD after a traumatic event. It looks at how to best support both the child and their caregiver through therapy and surveys.
Rochester, New YorkAges 8–17 - NCT06957808Recruiting
Diroximel fumarate brain health study for schizophrenia
This trial tests if a drug called diroximel fumarate can help increase a natural antioxidant (glutathione) in the brain for people with schizophrenia. It aims to see if lowering inflammation and boosting brain protection might improve symptoms.
London, Greater LondonAges 18–65 - NCT06958536RecruitingPhase 2
Testing a new drug for moderate to severe Crohn's disease
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
Tucson, ArizonaAges 18–75 - NCT06958692RecruitingPhase 3
Testing a new antidepressant combination for depression
This study tests a new combination of two medications (dextromethorphan and bupropion) as a treatment for major depressive disorder. It may be an option if you have not already tried many antidepressants that didn't work.
Beijing, Beijing MunicipalityAges 18–65 - NCT06958835Recruiting
Linezolid plus standard care for staph bloodstream infections
This trial tests whether adding linezolid, an antibiotic that stops bacteria from making proteins, to usual care works better for treating Staphylococcus aureus bloodstream infections. You may be eligible if you have this infection and are hospitalized.
Aarau, Canton of AargauAges 18 years+ - NCT06959004Recruiting
Does substance P trigger migraine attacks without aura?
This study tests whether a substance called substance P can cause migraine attacks in people who have migraine without aura. Results may help understand new ways to prevent or treat migraine.
Glostrup MunicipalityAges 18–65 - NCT06959043Recruiting
Diet and exercise for type 2 diabetes
This study tests if a plant-based diet and exercise program can improve blood sugar control in people with type 2 diabetes. Participants will live in a hospital for 4 weeks to follow the program closely.
São Paulo, São PauloAges 45–70 - NCT06959095RecruitingPhase 3
Depemokimab for COPD with type 2 inflammation
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
Loxahatchee Groves, FloridaAges 40–80 - NCT06959251Recruiting
Glycine and magnesium with thiamine for primary ciliary dyskinesia
This trial tests whether a combination of glycine, magnesium, and thiamine can help people with primary ciliary dyskinesia (a condition that affects the tiny hairs in your lungs). It aims to see if these supplements improve breathing and reduce lung problems.
Mexico CityAges 5 years+ - NCT06960213RecruitingPhase 3
Study of ADX-324 for preventing HAE attacks
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
Litchfield Park, ArizonaAges 18 years+ - NCT06960564Recruiting
Hyaluronic acid injection for knee osteoarthritis
This study tests whether a hyaluronic acid injection (a natural lubricant for joints) can reduce inflammation markers in the knee for people with osteoarthritis. It may be a good option if you have moderate knee pain that hasn't improved with other treatments.
IstanbulAges 45–75 - NCT06960928RecruitingPhase 3
Low dose sirolimus for long COVID
This trial tests if a low dose of sirolimus, a medicine that calms the immune system, can help people with long COVID. If you have had long COVID symptoms for at least 6 months, like severe fatigue, brain fog, or chest pain, you may be able to join.
New York, New YorkAges 18 years+ - NCT06961006RecruitingPhase 2
Study of an experimental vaccine plus pembrolizumab for melanoma
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab (Keytruda) in people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps the immune system fight the cancer better.
Springdale, ArkansasAges 18 years+ - NCT06961214RecruitingPhase 3
Testing a new biologic for COPD with type 2 inflammation
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
Sheffield, AlabamaAges 40–80 - NCT06961968RecruitingPhase 3
Schizophrenia medication withdrawal study
This study tests whether patients with schizophrenia can safely stop or reduce their current medication without worsening symptoms. It is designed for people who need ongoing psychiatric care.
Rogers, ArkansasAges 18–65 - NCT06962098RecruitingPhase 2
Study of isuzinaxib for diabetic kidney disease
This trial tests an investigational drug called isuzinaxib (APX-115) for people with type 2 diabetes and diabetic kidney disease (DKD). The goal is to see if it can help protect kidney function. Participants must have stable kidney lab values and be on certain blood pressure or diabetes medications.
Ansan-siAges 19 years+ - NCT06963034RecruitingPhase 3
Study of a new medicine for adults with schizophrenia
This trial tests an investigational medicine called NBI-1117568 in adults with schizophrenia who are currently having a relapse or worsening of symptoms and need to stay in the hospital. The goal is to see if the medicine is safe and effective.
Bryant, ArkansasAges 18–65 - NCT06964087RecruitingPhase 2
Testing OPT101 for type 1 diabetes
This trial tests an investigational drug called OPT101 in people with type 1 diabetes. It aims to see how the drug works in the body and whether it can help preserve insulin production, especially in those diagnosed recently or within the last 20 years.
Birmingham, AlabamaAges 18–50 - NCT06964620RecruitingEarly Phase 1
Sanggua Tablets for prediabetes and mild type 2 diabetes
This trial tests whether Sanggua Tablets, an herbal medicine, can help people with prediabetes or mild type 2 diabetes improve their blood sugar control without needing other medications.
Wuhan, HubeiAges 18–70 - NCT06964815Recruiting
Silibinin plus standard treatment for newly diagnosed glioblastoma
This trial tests whether adding the supplement silibinin (milk thistle extract) to the usual radiation and chemotherapy can help people with a certain type of aggressive brain cancer live longer. The study is for patients whose tumor tests positive for a protein called STAT3 and whose cancer has not spread.
Bologna, BOAges 18–99 - NCT06965998RecruitingPhase 2/Phase 3
Comparing two doses of rivaroxaban for leg vein clots
This trial tests if a full dose of rivaroxaban (a blood thinner) works better than a lower preventive dose for treating a superficial vein clot in the leg. It aims to find the safest and most effective way to stop the clot from getting worse or causing a more serious clot.
Ottawa, OntarioAges 18 years+
Hear when a new Placebo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo?
- Yes. Clin2 currently lists 5,230 recruiting placebo studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.